Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study

Diabetes and Metabolism

Volumn 36, Issue 2, 2010, Pages 137-143

  Khalili, P ^a,b   Flyvbjerg, A ^c   Frystyk, J ^c   Lundin, F ^d   Jendle, J ^a,b   Engstrom G ^e   Nilsson, P M ^b,e  

^a CENTRAL HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Värmland County Research Council   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Adiponectin; Cardiovascular events; Coronary events; Glucose metabolism; Long term; Prospective study; Stroke

Indexed keywords

ADIPONECTIN; GLUCOSE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE;

ADIPONECTIN; ADULT; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; SMOKING; SWEDEN;

EID: 77953286453     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.10.004     Document Type: Article

References (37)

1. Staiger H., Tschritter O., Machann J., Thamer C., Fritsche A., Maerker E., et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 11 (2003) 368-372
2. Trujillo M.E., and Scherer P.E. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
3. Wannamethee S.G., Lowe G.D., Rumley A., Cherry L., Whincup P.H., and Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 30 (2007) 1200-1205
4. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
5. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
6. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 36 (2003) 226-228
7. Choi K.M., Lee J., Lee K.W., Seo J.A., Oh J.H., Kim S.G., et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 61 (2004) 75-80
8. Lindsay R.S., Resnick H.E., Zhu J., Tun M.L., Howard B.V., Zhang Y., et al. Adiponectin and coronary heart disease: the strong heart Study. Arterioscler Thromb Vasc Biol 25 (2005) e15-e16
9. Bodary P.F., and Eitzman D.T. Adiponect vascular protection from the fat?. Arterioscler Thromb Vasc Biol 26 (2006) 235-236
10. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 15 117 (2008) 216-223
11. Wu X., Mahadev K., Fuchsel L., Ouedraogo R., Xu S.Q., and Goldstein B.J. Adiponectin suppresses IkappaB kinase activation induced by tumor necrosis factor-alpha or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab 293 (2007) E1836-E1844
12. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
13. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
14. Chulze M.B., Shai I., Rimm E.B., Li T., Rifai N., and Hu F.B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
15. Koenig W., Khuseyinova N., Baumert J., Meisinger C., and Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 48 (2006) 1369-1377
16. Tsutamoto T., Tanaka T., Sakai H., Ishikawa C., Fujii M., Yamamoto T., et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28 (2007) 1723-1730
17. Lim S., Koo B.K., Cho S.W., Kihara S., Funahashi T., Cho Y.M., et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 196 (2008) 398-404
18. Sattar N., and Nelson S.M. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 93 (2008) 3299-3301
19. Berglund G., Nilsson P., Eriksson K.F., Nilsson J.A., Hedblad B., Kristenson H., et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 247 (2000) 19-29
20. Swarbrick M.M., and Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6 (2008) 87-102
21. Hedblad B., Nilsson P., Janzon L., and Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 17 (2000) 299-307
22. Heding L. A simplified insulin radioimmunoassay method. In: Donato L., and Sirchis J. (Eds). Labelled proteins in tracer studies (1966), Euratom, Brussels 345-350
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
24. Frystyk J., Tarnow L., Hansen T.K., Parving H.H., and Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48 (2005) 1911-1918
25. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278 (2003) 40352-40363
26. Dekker J.M., Funahashi T., Nijpels G., Pilz S., Stehouwer C.D., Snijder M.B., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 93 (2008) 1489-1496
27. Rathmann W., and Herder C. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology". Horm Metab Res 39 (2007) 1-2
28. Teoh H., Strauss M.H., Szmitko P.E., and Verma S. Adiponectin and myocardial infarction: A paradox or a paradigm?. Eur Heart J 27 (2006) 2266-2268
29. Hoffstedt J., Arvidsson E., Sjolin E., Wahlen K., and Arner P. Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab 89 (2004) 1391-1396
30. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
31. Cavusoglu E., Ruwende C., Chopra V., Yanamadala S., Eng C., Clark L.T., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27 (2006) 2300-2309
32. Matsumoto M., Ishikawa S., and Kajii E. Association of adiponectin with cerebrovascular disease: a nested case-control study. Stroke 39 (2008) 323-328
33. Frystyk J., Berne C., Berglund L., Jensevik K., Flyvbjerg A., and Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92 (2007) 571-576
34. Inoue T., Kotooka N., Morooka T., Komoda H., Uchida T., Aso Y., et al. High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 100 (2007) 569-574
35. von Eynatten M., Humpert P.M., Bluemm A., Lepper P.M., Hamann A., Allolio B., et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 199 (2008) 123-128
36. Eguchi K., Tomizawa H., Ishikawa J., Hoshide S., Numao T., Fukuda T., et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 30 (2007) 23-30
37. Karakas M, Zierer A, Herder C, Baumert J, Meisinger C, Koenig W, et al. Leptin, adiponectin, their ratio and risk of coronary heart disease: Results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis 2009 [Epub ahead of print].